GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Virax Biolabs Group
Virax Biolabs is a company specializing in viral disease diagnostics. Its stock price is volatile and driven by news of new test developments, especially during periods of heightened awareness of infectious diseases.
Share prices of companies in the market segment - Medanalysis
Virax Biolabs Group is an immunology company that develops and markets diagnostic tests for detecting T-cell immunity to viral diseases. We've categorized it as a "Medanalysis" company. The chart below shows how investors view the immunodiagnostics sector.
Broad Market Index - GURU.Markets
Virax Biolabs is a biotech company developing diagnostic tests and a platform for monitoring the immune response to viral diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the diagnostics sector.
Change in the price of a company, segment, and market as a whole per day
VRAX - Daily change in the company's share price Virax Biolabs Group
The daily price change of Virax Biolabs Group, a diagnostics company, reflects the volatility of the sector. The indicator demonstrates sensitivity to news about the development of new tests and changes in the epidemiological situation.
Daily change in the price of a set of shares in a market segment - Medanalysis
Virax Biolabs Group offers diagnostic tests and immune profiling solutions, operating globally. The medical diagnostics sector is sensitive to pandemics and innovation. The chart below shows the volatility in this niche, allowing you to compare VRAX's performance with other companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Virax Biolabs is a company specializing in viral disease diagnostics. Demand for its products can spike during epidemics, creating a unique, event-driven dynamic in its stock that impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Virax Biolabs Group
For Virax Biolabs Group, year-over-year performance tells the story of its performance in the diagnostics market. Its market capitalization change over the past 12 months reflects its success in distributing infectious disease tests, as well as progress in developing its proprietary platform for assessing T-cell immunity, its main bet for the future.
Annual dynamics of market capitalization of the market segment - Medanalysis
Virax, a biotech company, focuses on viral disease diagnostics. Its performance relative to the sector will demonstrate the extent to which investors believe in its scientific platform and its ability to commercialize its tests, especially in a post-pandemic world.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Virax Biolabs, a diagnostics company, is reflecting the demand for viral disease testing with its growth. Following the pandemic boom, its ability to stay ahead of the market depends on the development and commercialization of new tests needed in peacetime, which poses a significant challenge.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Virax Biolabs Group
Virax is a biotech company focused on immunology and diagnostics. Its monthly performance reflects progress in the commercialization of its T-cell assays and the development of therapeutics. Regulatory news is key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
The medical testing and diagnostics market, particularly in the field of immunology, is critical to healthcare. The dynamics of this sector, shown in the graph, reflect the demand for new tests. Companies like Virax Biolabs are developing products in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Virax Biolabs, a diagnostics company, can experience explosive growth during disease outbreaks. Its stock price is unpredictable and depends on the epidemiological situation and news, rather than general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Virax Biolabs Group
Shares of Virax Biolabs, a company working in viral diagnostics, are sensitive to news about epidemics. Weekly price movements can fluctuate sharply in response to reports of new virus outbreaks and demand for their testing systems. The chart below shows how short-term public health events affect the company.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Virax Biolabs operates in the field of viral diagnostics. Demand for its products can fluctuate dramatically depending on the epidemiological situation. The chart shows how sensitive its stock is to news about new viruses and pandemics, distinguishing it from the more stable medical equipment sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Virax Biolabs operates in the medical diagnostics sector. This chart compares its weekly performance to the broader market. It helps understand how resilient its business, which focuses on basic healthcare needs, is to general economic downturns.
Market capitalization of the company, segment and market as a whole
VRAX - Market capitalization of the company Virax Biolabs Group
Virax Biolabs Group's market capitalization is the valuation of its platform for diagnosing the immune response to viral diseases. The company's value depends on the demand for its T-cell tests. The chart shows how investors value its technology in a world where immune monitoring is becoming increasingly important.
VRAX - Share of the company's market capitalization Virax Biolabs Group within the market segment - Medanalysis
Virax Biolabs's market share in the medical diagnostics sector reflects its focus on immunological testing. Its market share is driven by its T-cell immunity assessment platform, which could be useful for monitoring immune responses to viruses and vaccines in a post-pandemic world.
Market capitalization of the market segment - Medanalysis
The chart shows the total market capitalization of companies involved in viral disease diagnostics. Virax Biolabs is one of the players in this field. The graph shows how the market views this industry post-pandemic and its preparedness for future threats.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market valuation of rapid viral diagnostics. Virax Biolabs Group's market capitalization reflects demand for its tests that detect immune responses to viruses. The line shows how this small life science company is fighting for its share of the global healthcare economy.
Book value capitalization of the company, segment and market as a whole
VRAX - Book value capitalization of the company Virax Biolabs Group
Virax Biolabs Group's book value represents its scientific capital. The chart below reflects the valuation of its development pipeline in viral diagnostics, particularly T-cell immunity assays. The line's growth signals advances in research, which is the diagnostic company's core asset.
VRAX - Share of the company's book capitalization Virax Biolabs Group within the market segment - Medanalysis
Virax Biolabs's core assets are its laboratories and diagnostic equipment for developing viral disease tests. The chart shows the company's share of this scientific infrastructure, which forms the physical core of its immune response monitoring products.
Market segment balance sheet capitalization - Medanalysis
Against the backdrop of the capital-intensive pharmaceutical industry, Virax Biolabs has chosen the diagnostics industry. Its business requires a unique yet focused resource base—advanced laboratories. The graph illustrates the scale of the industry, in which Virax occupies its high-tech, less capital-intensive niche.
Book value of all companies included in the broad market index - GURU.Markets
Virax Biolabs develops diagnostic tests for viral diseases. The company's assets are not hospitals, but laboratories and intellectual property that enable the creation of "indicators" for the immune system. The chart below shows the financial weight behind this early detection technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Virax Biolabs Group
Virax Biolabs is a biotechnology company specializing in viral disease diagnostics. Its market value is derived from its diagnostic platform and its ability to commercialize new, more accurate tests.
Market to book capitalization ratio in a market segment - Medanalysis
Virax Biolabs Group is a company specializing in viral disease diagnostics. Its value lies in its testing technologies. This chart shows how its market valuation, which depends on diagnostic demand and the epidemiological situation, relates to its tangible assets.
Market to book capitalization ratio for the market as a whole
Virax Biolabs Group specializes in the diagnostics and analysis of viral diseases. This chart shows how the market evaluates their diagnostic technologies and their potential to respond to emerging epidemiological threats. Fluctuations are often driven by global health news and the results of their tests.
Debts of the company, segment and market as a whole
VRAX - Company debts Virax Biolabs Group
Virax Biolabs, a company specializing in viral disease diagnostics, leverages its financial structure to develop and commercialize its tests. This chart shows how the company is investing in R&D and regulatory approvals to bring its diagnostic solutions to market, particularly in the field of immunology.
Market segment debts - Medanalysis
Virax Biolabs is a company specializing in viral diagnostics. Its business requires investment in the development and validation of new tests. This chart shows how its debt policy reflects its stage of development and how it funds its R&D programs to bring new diagnostic solutions to market, especially in light of the increased attention to viral threats.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Virax Biolabs Group
Jeffs' Brands is a holding company that acquires and develops brands that sell on Amazon and other online marketplaces. Debt is often used in this model to acquire new brands. This chart shows how aggressively the company uses leverage to implement its M&A strategy in the e-commerce world.
Market segment debt to market segment book capitalization - Medanalysis
Virax Biolabs is a company specializing in the development of diagnostic tests for viral diseases. This chart compares its debt load to the overall market capitalization of the entire medical analytics sector. It helps understand how a small company finances its research and development to compete in the diagnostics market.
Debt to book value of all companies in the market
Virax Biolabs Group operates in the field of viral disease diagnostics, providing tests and analytical tools. Demand for its products can be volatile, as demonstrated by the pandemic. This graph of total debt in the economy helps assess how the company is managing its finances and preparing for future public health challenges.
P/E of the company, segment and market as a whole
P/E - Virax Biolabs Group
This chart shows the valuation of Virax Biolabs, a medical diagnostics company. The price-to-earnings ratio (if any) will reflect the demand for its tests and investors' faith in its scientific platform. This is a bet that its diagnostic solutions will be in demand to combat viral diseases.
P/E of the market segment - Medanalysis
Virax Biolabs Group is a company specializing in viral disease diagnostics. It develops and markets tests and diagnostic kits, as well as a platform for assessing T-cell immunity. This chart shows the average rating for the medical analysis sector, reflecting how the market values innovations in diagnostics and immune response monitoring.
P/E of the market as a whole
Virax Biolabs Group is a biotech company specializing in diagnostics and monitoring the immune response to viral diseases. The company develops tests that can predict a person's immunity to viruses. This risk appetite chart helps understand how investors evaluate innovative diagnostic platforms.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Virax Biolabs Group
Virax Biolabs is a company specializing in viral disease diagnostics, specifically the development of tests for assessing T-cell immunity. This chart shows future revenue expectations, which depend on demand for innovative diagnostic solutions and the successful commercialization of its testing platforms.
%20P%2FE%20Virax%20Biolabs%20Group&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Virax-Biolabs-Group&v=1772513885788 "Chart of the company's future (projected) P/E Virax Biolabs Group")
Future (projected) P/E of the market segment - Medanalysis
Virax Biolabs Group specializes in diagnostic tests for viral diseases. This chart reflects market expectations for the company's future profitability in a post-pandemic world. It shows whether investors believe in sustainable demand for its diagnostic solutions and its ability to compete with larger players in the medical technology market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772513885805 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Virax Biolabs Group specializes in diagnostic tests for viral diseases and T-cell immunology. Demand for their products depends on the epidemiological situation and government healthcare spending. The overall market environment, shown in this graph, influences healthcare system budgets and their willingness to invest in advanced diagnostics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513885846 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Virax Biolabs Group
Virax Biolabs Group specializes in diagnostic tests and immunological research products, particularly for viral diseases. The company's financial performance depends on demand for its tests from laboratories and healthcare institutions. This chart shows how disease outbreaks and overall diagnostic demand impact financial performance.
Profit of companies in the market segment - Medanalysis
Virax Biolabs Group specializes in developing diagnostic tests and solutions for viral diseases. This chart, showing overall profitability in the medical diagnostics sector, reflects the importance of timely threat detection. Virax's ability to quickly develop and commercialize accurate tests directly impacts its contribution to the overall industry profitability.
Overall market profit
Virax Biolabs Group operates in the field of viral disease diagnostics, offering tests and analytical tools. Demand for its products can surge during epidemics, but otherwise depends on overall healthcare spending. Being a public health company, its business model is unique.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Virax Biolabs Group
Virax Biolabs Group specializes in diagnostic tests for viral diseases. The future revenue projections you see depend on the development and commercialization of new tests. Analysts are assessing the company's potential in the diagnostics market, which is sensitive to epidemiological conditions and technological innovations.
%20profit%20of%20the%20company%20Virax%20Biolabs%20Group&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Virax-Biolabs-Group&v=1772513886014 "Graph of future (projected) profit of the company Virax Biolabs Group")
Future (predicted) profit of companies in the market segment - Medanalysis
Virax Biolabs Group specializes in developing diagnostic tests for viral diseases. This chart reflects profitability expectations for the entire medical analytics sector. It allows one to assess how the company's business, dependent on the epidemiological situation and demand for rapid diagnostics, aligns with overall healthcare trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772513886135 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Virax Biolabs Group specializes in diagnostic tests for viral diseases. Demand for its products can be situational (disease outbreaks), but also depends on overall healthcare spending. This chart, showing economic forecasts, impacts healthcare budgets, which may spend more on prevention and diagnostics during periods of growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513886153 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Virax Biolabs Group
Virax Biolabs Group specializes in developing diagnostic tests for viral diseases. For a company in the diagnostics sector, especially after the pandemic, this chart is crucial. It shows how investors value its technology platform and test portfolio, factoring in future sales potential should new viral threats emerge.
P/S market segment - Medanalysis
Virax Biolabs Group specializes in the development and distribution of diagnostic tests for viral diseases. The company strives to provide accurate and rapid solutions for detecting infections. This chart shows how the market values revenue in the medical diagnostics sector, which helps understand how investors view Virax Biolabs' product line and market strategy.
P/S of the market as a whole
Virax Biolabs Group is an innovative company specializing in viral disease diagnostics, including a platform for assessing T-cell immunity. This chart helps understand how the market is valuing companies in the diagnostics sector, especially after the pandemic, against the backdrop of overall economic trends.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Virax Biolabs Group
Virax Biolabs Group specializes in viral disease diagnostics, including a T-cell immunity analysis platform. This chart shows how investors value the company relative to its future revenue. It reflects the market's confidence in the commercial potential of its diagnostic solutions and future demand for innovative assays.
%20P%2FS%20Virax%20Biolabs%20Group&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Virax-Biolabs-Group&v=1772513886474 "The graph of the company's future (projected) P/S Virax Biolabs Group")
Future (projected) P/S of the market segment - Medanalysis
Virax Biolabs Group specializes in viral disease diagnostics, including a platform for assessing T-cell immunity. The chart shows the average estimated future revenue for the medical diagnostics sector. It helps understand how the market views Virax's technology and its commercial prospects in a post-pandemic world compared to other diagnostics companies.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772513886566 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Virax Biolabs Group (VRAX) specializes in viral disease diagnostics. Demand for their tests depends on the epidemiological situation and healthcare system needs, not on general economic trends. This chart does not reflect their potential, which could increase sharply in the event of a new pandemic or outbreak.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513886621 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Virax Biolabs Group
This chart shows the initial revenue of Virax Biolabs, a diagnostics company. Revenue is generated from sales of tests and diagnostic kits aimed at detecting viral diseases. Growth will reflect the successful adoption of its products in medical laboratories and their ability to compete in the immunodiagnostics market.
Sales of companies in the market segment - Medanalysis
Virax Biolabs Group specializes in viral disease diagnostics. As its revenue structure develops, it will reflect a shift in sales of diagnostic tests and a shift in branded products, such as T-cell tests, reflecting its focus on innovative immunology solutions.
Overall market sales
Virax Biolabs Group specializes in diagnostic tests for viral diseases. Demand for its products depends on the epidemiological situation and government healthcare programs. The overall economic situation, shown in this chart, influences the budgets governments and organizations are willing to allocate for disease monitoring and prevention, especially after pandemics.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Virax Biolabs Group
Virax Biolabs Group specializes in diagnostic tests for viral diseases, including a platform for assessing T-cell immunity. The company's future revenue depends on the commercialization of its diagnostic products. This chart reflects analyst forecasts for the immunological diagnostics market and the potential of the company's technologies.
%20sales%20of%20the%20company%20Virax%20Biolabs%20Group&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Virax-Biolabs-Group&v=1772513886826 "Schedule of future (projected) sales of the company Virax Biolabs Group")
Future (projected) sales of companies in the market segment - Medanalysis
Virax Biolabs Group specializes in diagnostic tests for viral diseases, including T-cell assays. This chart shows the forecast for the medical analytics sector. It reflects the global demand for innovative diagnostic tools for immune response monitoring, a core niche for Virax.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772513886883 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Investments in diagnostics and healthcare, which can be projected from this graph, determine the prospects of Virax Biolabs Group. The company, which develops diagnostic tests for viral diseases, depends on healthcare system budgets and their willingness to purchase innovative solutions for infection monitoring and control.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513886934 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Virax Biolabs Group
Virax Biolabs is a biotechnology company specializing in diagnostic tests for viral diseases. This chart shows its financial results, which can be highly volatile. Profitability is highly dependent on demand for specific tests, such as during pandemics, and competition in the diagnostics sector.
Market segment marginality - Medanalysis
Virax Biolabs Group develops and sells diagnostic tests for viral diseases. The company's profitability depends on demand for its tests and its ability to quickly bring new diagnostic solutions to market. This chart shows the average profitability in the sector. It helps assess Virax Biolabs' competitiveness in the medical diagnostics market.
Market marginality as a whole
Virax Biolabs Group specializes in diagnostic tests for viral diseases. Demand for its products can surge during epidemics, but at other times depends on overall healthcare spending. This graph, reflecting the state of the economy, influences public and private funding for preventive medicine and epidemiological surveillance.
Employees in the company, segment and market as a whole
Number of employees in the company Virax Biolabs Group
Virax Biolabs Group specializes in diagnostic tests for viral diseases. This chart shows the size of the team dedicated to test development, certification, and marketing. This growth reflects the company's efforts to bring new diagnostic solutions to market and adapt to changing testing demand following global pandemics.
Share of the company's employees Virax Biolabs Group within the market segment - Medanalysis
Virax Biolabs Group specializes in developing diagnostic tests for viral diseases. Its team consists of scientists and laboratory diagnostics specialists. This chart shows the company's share of the total number of employees in the medical testing sector. This reflects its research programs and ability to bring new diagnostic solutions to market.
Number of employees in the market segment - Medanalysis
Virax Biolabs Group specializes in the development and sale of diagnostic tests for viral diseases. This chart, illustrating employment in the medical analytics sector, is an important indicator. The growth in the number of lab technicians and scientists in this field reflects the increased focus on epidemiological surveillance and the need for fast and accurate diagnostic tools.
Number of employees in the market as a whole
Virax Biolabs Group specializes in viral disease diagnostics. This overall employment chart reflects the overall health system. Economic stability associated with high employment allows governments and companies to allocate more resources to monitoring and preventing epidemics, increasing demand for Virax diagnostic solutions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Virax Biolabs Group (VRAX)
Virax Biolabs is a biotech company specializing in diagnostics and immune response monitoring, including for viral diseases. This metric reflects the assessment of their diagnostic platform and R&D. In the medical technology and analytics industry, value is created by the precision of technology and patents, not by the number of lab technicians, which leads to a high cost per employee.
%20of%20the%20company%20Virax%20Biolabs%20Group%20(VRAX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Virax-Biolabs-Group-VRAX&v=1772513887517 "Chart of market capitalization per employee (in thousands of dollars) of the company Virax Biolabs Group (VRAX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Virax Biolabs Group specializes in viral diagnostic solutions. In the field of medical analysis and biotechnology, scientific research and patents play a key role, not a large staff. This metric demonstrates the value the market assigns to each employee, which often reflects the level of innovation and the potential of a company's intellectual property.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772513887523 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Virax Biolabs develops diagnostic tests for viral diseases. In medical diagnostics, value is determined by the accuracy, speed, and uniqueness of technologies. This metric demonstrates how the market values a company's intellectual capital, allowing a small team of scientists to create a product in demand by the global healthcare system.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513887528 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Virax Biolabs Group (VRAX)
Virax Biolabs is a company specializing in immunology diagnostic tests, specifically T-cell tests for viral threats. This chart shows how successfully their team (scientists, sales) is commercializing these niche tests. It reflects whether the company is generating revenue from its products or is still in the R&D phase.
%20Chart%20Virax%20Biolabs%20Group%20(VRAX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Virax-Biolabs-Group-VRAX&v=1772513887548 "Company Profit Per Employee (in thousands of dollars) Chart Virax Biolabs Group (VRAX)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Virax Biolabs Group specializes in diagnostic tests for viral diseases. This indicator demonstrates the company's ability to efficiently manufacture and market its products. In the medical analytics sector, success depends on the speed of bringing relevant tests to market and the automation of laboratory processes, which allows for the processing of large volumes of tests by a small team.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772513887552 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Virax Biolabs Group (VRAX) is a company specializing in viral disease diagnostics, specifically T-cell tests (e.g., for COVID-19 or monkeypox). It's a biotech company in the diagnostics space. Its profit per employee depends on the success of commercialization and regulatory approval of its unique diagnostic platforms. It's a knowledge-intensive, not labor-intensive, business.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513887572 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Virax Biolabs Group (VRAX)
Virax Biolabs Group specializes in diagnostic tests for viral diseases. This chart shows how the company is commercializing its products globally. The growth in revenue per employee reflects the demand for their tests and the effectiveness of their distribution network and laboratory services.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Virax-Biolabs-Group-VRAX&v=1772513887577 "Sales chart per company employee Virax Biolabs Group (VRAX)")
Sales per employee in the market segment - Medanalysis
Virax Biolabs specializes in diagnostics and immune response monitoring, specifically T-cell immunity. It's an R&D-intensive medical device company. This graph shows the current stage of commercialization for their technology. Their team's productivity reflects their ability to translate scientific research into marketable tests.
Sales per employee for the market as a whole
PROG Holdings (PRG) offers lease-to-own solutions for consumers, often directly at retailers' points of sale (e.g., for furniture or electronics). It is a fintech business that manages risk and payments. This chart reflects the technological sophistication of their platform. High revenue per employee is achieved through the automation of scoring, billing, and customer service.
Short shares by company, segment and market as a whole
Shares shorted by company Virax Biolabs Group (VRAX)
Virax Biolabs (VRAX) operates in the medical diagnostics sector. Since the pandemic, this market has become oversaturated. This chart shows the volume of short positions. Bears may doubt the company's diagnostic tests (for example, for T-cells) will be in demand or will be able to compete in this challenging market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Virax-Biolabs-Group-VRAX&v=1772513887672 "Short Shares Chart for the Company Virax Biolabs Group (VRAX)")
Shares shorted by market segment - Medanalysis
Virax Biolabs (VRAX) specializes in diagnostics, specifically T-cell immune response analysis. The chart below shows the overall short position in the medical diagnostics sector. It reflects the skepticism investors have about the commercialization of new diagnostic platforms post-pandemic.
Shares shorted by the overall market
Virax Biolabs is a company working in diagnostics, specifically T-cell immunity. This chart illustrates the overall market pessimism. When fears mount, investors become skeptical of small diagnostic companies. They fear that VRAX won't have the resources to commercialize its tests, and are selling off illiquid shares of microcaps.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Virax Biolabs Group (VRAX)
This oscillator is a barometer of pandemic speculation for Virax Biolabs. The company supplies diagnostic tests and manages a brand of T-cell tests. "Overheating" (above 70) occurs during outbreaks of new viruses (such as COVID-19 and monkeypox). A decline in demand for tests during "peacetime" and competition lead to "oversold" conditions (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Virax-Biolabs-Group-VRAX&v=1772513887741 "RSI 14 indicator chart for the company's stock Virax Biolabs Group (VRAX)")
RSI 14 Market Segment - Medanalysis
Virax Biolabs is a biotech company specializing in diagnostics. They develop and market tests (including T-cell tests) for viral diseases such as COVID-19, MPOX, and influenza. This chart reflects the overall sentiment in the medical testing and diagnostics sector, helping to assess how the market views the industry as a whole.
RSI 14 for the overall market
Virax Biolabs Group (VRAX) operates in the diagnostics field, specializing in viral diseases. This sector has attracted much attention but remains volatile. This market "temperature" indicator helps understand the overall situation. During periods of panic (oversold conditions), investors may dump diagnostics stocks if there is no news to support them. Euphoria, on the other hand, can support high valuations in anticipation of new developments.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRAX (Virax Biolabs Group)
Virax Biolabs is a biotech company focused on immunology. It develops diagnostic T-cell tests (for assessing immunity to viruses) and therapeutics for viral diseases. This chart shows the speculative average 12-month price target from analysts based on their assessment of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRAX-Virax-Biolabs-Group&v=1772513887863 "A chart showing analyst consensus forecasts for the expected stock price. VRAX (Virax Biolabs Group)")
The difference between the consensus estimate and the actual stock price VRAX (Virax Biolabs Group)
Virax is a biotech company developing a platform for measuring T-cell immunity (the immune response) to various viruses. This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see for this diagnostic technology in a post-COVID world.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRAX-Virax-Biolabs-Group&v=1772513887892 "A chart showing the difference between the consensus forecast and the actual stock price. VRAX (Virax Biolabs Group)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Virax Biolabs is an R&D company focused on diagnostics. It develops tests to assess T-cell immunity (response to viruses). This chart reflects analysts' overall expectations for the entire medical testing sector. It shows whether experts believe there will be demand for immune diagnostics after COVID.
Analysts' consensus forecast for the overall market share price
Virax Biolabs is a company specializing in diagnostics and immune system profiling to combat viral diseases. This chart shows the overall market appetite. For VRAX, an early-stage, high-risk company, overall market optimism (the rising chart) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Virax Biolabs Group
Virax is an immune biotech. They don't treat; they measure: their signature feature is a diagnostic R&D platform (T-cell) for measuring (in vitro) the strength of a patient's immune response to viruses (COVID, influenza). This graph is a pure indicator of their R&D. It reflects their (very slow) path to commercialization and their speculative bet on immune monitoring.
AKIMA Market Segment Index - Medanalysis
Virax Biolabs is a biotech company specializing in diagnostics and immune profiling, particularly in the context of viral diseases. They aim to understand how T cells respond to threats. This chart compares their composite index to the sector, showing how their analytical approach outperforms the competition.
The AKIM Index for the overall market
Virax Biolabs is a biotech company focused on viral diagnostics and immunological profiling (ViraxClear). This chart, showing the average (global/US) market share, serves as a benchmark. It helps assess how VRAX, a diagnostics player, stacks up against overall macroeconomic trends.
